Episode Details

Non-invasive neurostimulation technology can significantly slow cognitive and functional decline in Alzheimer's patients by stimulating brain activity with a new approach.

In this episode, Christian Howell, CEO of Cognito Therapeutics, highlights the limited progress in Alzheimer's disease modification, noting recent monoclonal antibodies targeting amyloid plaque but with concerns about efficacy and cost. He also discusses Cognito's groundbreaking work on Alzheimer's treatments and explains how their innovative device, Spectris, offers a promising non-invasive therapy. Christian explains how Cognito is actively gathering evidence for Spectris' approval and market launch, envisioning its application for various neurodegenerative conditions, broader aging-related cognitive decline, and metabolic health, showcasing the potential of neurostimulation in driving biological brain changes. 

Tune in to discover the future of non-invasive neurostimulation and the benefits this new technology could bring to Alzheimer's patients!

Resources:

• Connect with and follow Christian Howell on LinkedIn.
• Follow Cognito Therapeutics on LinkedIn and explore their Website.
• Find the Nature paper about Spectris here.